Carl R. Alving
34Patents
15h-index
41Co-inventors
81Inventor score
Filing activity: Mar 29, 1978 → Apr 27, 2018
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US4186183A | Liposome carriers in chemotherapy of leishmaniasis | Emerging Cross-Sectional Technologies | 166 | Expired |
| US5059591A | Drug preparations of reduced toxicity | Human Necessities | 100 | Expired |
| US6090406A | Potentiation of immune responses with liposomal adjuvants | Emerging Cross-Sectional Technologies | 100 | Expired |
| US6797276B1 | Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response | Emerging Cross-Sectional Technologies | 89 | Expired |
| US5910306A | Transdermal delivery system for antigen | Emerging Cross-Sectional Technologies | 70 | Expired |
| US4897384A | Drug preparations of reduced toxicity | Human Necessities | 61 | Expired |
| US5980898A | Adjuvant for transcutaneous immunization | Human Necessities | 54 | Expired |
| US5916588A | Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use | Human Necessities | 50 | Expired |
| US6007838A | Process for making liposome preparation | Emerging Cross-Sectional Technologies | 46 | Expired |
| US4416872A | Treatment of malaria with liposomes containing 8-aminoquinoline derivatives and glycoconjugates | Emerging Cross-Sectional Technologies | 25 | Expired |
| US6110492A | Immunogenic compositions | Emerging Cross-Sectional Technologies | 22 | Expired |
| US6093406A | Vaccine for induction of immunity to malaria | Emerging Cross-Sectional Technologies | 22 | Expired |
| US4302459A | Liposome carriers in leishmaniasis chemotherapy with 8-aminoquinoline derivatives | Emerging Cross-Sectional Technologies | 21 | Expired |
| US5820880A | Liposomal formulation | Emerging Cross-Sectional Technologies | 20 | Expired |
| US5888519A | Encapsulated high-concentration lipid a compositions as immunogenic agents to produce human antibodies to prevent or treat gram-negative bacterial infections | Emerging Cross-Sectional Technologies | 19 | Expired |
| US7037499B1 | Adjuvant for transcutaneous immunization | Human Necessities | 14 | Expired |
| US4863874A | Method for detecting phosphatidylinositol through binding to Concanavalin A | Emerging Cross-Sectional Technologies | 10 | Expired |
| US4885256A | Monoclonal antibodies to cholesterol and methods | Emerging Cross-Sectional Technologies | 9 | Expired |
| US7419683B2 | Method of inhibiting side effects of pharmaceutical compositions containing amphiphilic vehicles or drug carrier molecules | Human Necessities | 8 | Expired |
| US4999344A | Phosphatidyl treatment of rapidly proliferating cells | Human Necessities | 8 | Expired |
| US7378097B2 | Use of penetration enhancers and barrier disruption methods to enhance the immune response of antigen and adjuvant | Emerging Cross-Sectional Technologies | 7 | Expired |
| US5753260A | Vaccines against sterols | Physics | 4 | Expired |
| US8148130B2 | T4 bacteriophage bound to a substrate | Chemistry; Metallurgy | 3 | Active |
| US5229376A | Encapsulated plant-derived phosphatidylinositol (PI) compositions for the prevention of mitogenically induced cell proliferation | Emerging Cross-Sectional Technologies | 3 | Expired |
| US6224902A | Vaccines against sterols | Physics | 2 | Expired |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.